These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 10087729)

  • 41. [Hormonal therapy (medical orchiectomy) in prostatic carcinoma].
    Studer UE; Münch D
    Schweiz Med Wochenschr; 1990 Jun; 120(24):881-7. PubMed ID: 2193381
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?
    Rohde V; Wellmann A; Fogt F; Weidner W; Katalinic A
    Oncol Rep; 2002; 9(6):1185-8. PubMed ID: 12375016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Controversies in the management of advanced prostate cancer.
    Tyrrell CJ
    Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hormonal management of advanced adenocarcinoma of the prostate.
    Miles BJ
    Henry Ford Hosp Med J; 1989; 37(1):16-8. PubMed ID: 2670839
    [No Abstract]   [Full Text] [Related]  

  • 46. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hormonal therapy of prostate cancer: current concepts and future prospects.
    Smith JA
    Clin Ther; 1988; 10(3):281-6. PubMed ID: 3078908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New possibilities in the hormonal therapy of metastatic carcinoma of the prostate].
    Cicin-Sain D; Pasini J
    Lijec Vjesn; 1989 Nov; 111(11):405-7. PubMed ID: 2699907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Unresolved questions in hormonal therapy for prostate cancer].
    Oishi K
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1928-33. PubMed ID: 8085843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormonal therapy in prostatic carcinoma.
    Resnick MI
    Urology; 1984 Nov; 24(5 Suppl):18-23. PubMed ID: 6388092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orchidectomy and oestrogens as secondary forms of treatment for metastatic prostatic cancer.
    Klijn JG; Nielander AJ; Alexieva-Figusch J; van Putten WL
    Prog Clin Biol Res; 1985; 185A():335-49. PubMed ID: 4034579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
    Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
    [No Abstract]   [Full Text] [Related]  

  • 55. Endocrine therapy for prostate cancer.
    Sagalowsky AI
    Spec Top Endocrinol Metab; 1985; 7():101-29. PubMed ID: 3914094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hormone therapy in advanced and generalized carcinoma of the prostate].
    Vachalovský V; Dvorácek J; Voboril V
    Cas Lek Cesk; 1998 Aug; 137(17):532-6. PubMed ID: 9787507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in the medical management of prostate cancer.
    Kirby RS
    Br J Clin Pract; 1996 Mar; 50(2):88-93. PubMed ID: 8731645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Medical treatment of prostate cancer].
    Lobel B; Cipolla B; Labrador J
    Rev Prat; 1994 Mar; 44(5):611-5. PubMed ID: 8066398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
    Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
    [No Abstract]   [Full Text] [Related]  

  • 60. Current concepts in the management of prostatic cancer.
    Schröder FH
    Am J Clin Oncol; 1988; 11 Suppl 1():S1-5. PubMed ID: 3389335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.